Results of ENGOT-OV16/NOVA Phase III trial of niraparib in platinum-sensitive ovarian cancer

Results of ENGOT-OV16/NOVA Phase III trial of niraparib in platinum-sensitive ovarian cancer

VJOncology

3 years
668 Views
Share
Want to watch this again later?
Sign in to add this video to a playlist. Login
0 0
Category:
Description:
Mansoor Mirza, MD of Rigshospitalet, Copenhagen University Hospital, Copenhagen, Denmark gives an overview of the results of the ENGOT-OV16/NOVA Phase III trial of maintenance with PARP-inhibitor niraparib versus placebo in patients with platinum-sensitive ovarian cancer (NCT01847274). According to Dr Mirza, the key take home message is that niraparib was effective as maintenance therapy for all patients in the trial. The biomarker for this treatment would be platinum-sensitvity. The treatment was effective regardless of BRCA status and regardless of HRD status. The hazard ratios for gBRCA mutated cohort was .27 and they saw an increase in median progression-free survival (PFS) from 5.5 to 21 months. In the non-gBRCA mutated cohort, the same efficacy was seen with hazard ratio of .45 and median PFS increased from 3.9 to 9 months. Dr Mirza also explains the results of the sub-population of non-gBRCA mutated, i.e. HRD positive and negative patients; both populations benefited from the drug. Therefore, all population benefited from the treatment.
Up Next Autoplay
National Brain Tumor Society to Provide Funding for ONC201 Trial in EGFR-Independent High-Grade Gliomas
National Brain Tumor Society to Provide Funding for ONC201 Trial in EGFR-Independent High-Grade Gliomas
Category: Acute Lymphoblastic Leukemia
2 Views
alexvarney 13 hours
Statement on New ASH Clinical Practice Guidelines on Sickle Cell Disease-Related Transfusion Support
Statement on New ASH Clinical Practice Guidelines on Sickle Cell Disease-Related Transfusion Support
Category: News
1 Views
Cancer-News 14 hours
GRACE Supportive Care Series:   Chemobrain with Guest, Lysa Buonnano
GRACE Supportive Care Series: Chemobrain with Guest, Lysa Buonnano
Category: Supportive Care
1 Views
cancergrace 3 days
ArcherDX Personalized Cancer Monitoring (PCM) Technology Designated by FDA as Breakthrough Device
ArcherDX Personalized Cancer Monitoring (PCM) Technology Designated by FDA as Breakthrough Device
Category: General
3 Views
Cancer-News 4 days
TOURMALINE-MM4: What's Next in Research?
TOURMALINE-MM4: What's Next in Research?
Category: Multiple Myeloma
2 Views
Cancer-News 4 days
TOURMALINE-MM4: Are There Safety Concerns?
TOURMALINE-MM4: Are There Safety Concerns?
Category: Multiple Myeloma
2 Views
Cancer-News 4 days
Minority Hematology Scholars to Study New Methods for Improving Blood Disease Treatments
Minority Hematology Scholars to Study New Methods for Improving Blood Disease Treatments
Category: News
0 Views
ash 4 days
What should clinicians know about patients with the H3 K27M mutation?
What should clinicians know about patients with the H3 K27M mutation?
Category: Brain Cancer
3 Views
Massachusetts General Hospital 4 days
TOURMALINE-MM4: Regulatory Pathway
TOURMALINE-MM4: Regulatory Pathway
Category: Multiple Myeloma
2 Views
Cancer-News 4 days
What Data Has Come Out of ONC201 in Adult Recurrent Glioblastoma?
What Data Has Come Out of ONC201 in Adult Recurrent Glioblastoma?
Category: Brain Cancer
1 Views
Massachusetts General Hospital 4 days